Clinical trial · Observational
Shotgun Sequencing in Diagnosing Febrile Neutropenia in Patients With Acute Myeloid Leukemia
Shotgun Sequencing for Etiologic Diagnosis of Febrile Neutropenia
NCT02856204CI-TRIAL-00038661completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research trial studies the shotgun sequencing of blood samples in diagnosing febrile neutropenia in patients with acute myeloid leukemia. Studying samples of blood from patients with acute myeloid leukemia in the laboratory may help identify pathogens and accurately diagnose infections such as febrile neutropenia.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
| Febrile Neutropenia | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cytology Specimen Collection Procedure | Other | — | UNRESOLVED |
| Laboratory Biomarker Analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Diagnostic (collection of blood samples)
- description
- Patients undergo collection of blood samples before and during the episode of febrile neutropenia for up to 6 weeks.
- interventionNames
- Other: Cytology Specimen Collection Procedure
- Other: Laboratory Biomarker Analysis
Primary outcomes (6)
- measure
- Detection of pathogens in patients with febrile neutropenia assessed by shotgun metagenomics
- timeFrame
- Up to 6 weeks
- description
- Will be compared to standard of care diagnostics in the detection of pathogens in patients with febrile neutropenia.
- measure
- Number and frequency of novel pathogens found
- timeFrame
- Up to 6 weeks
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with febrile neutropenia * A primary diagnosis of acute myeloid leukemia (AML) Exclusion Criteria: * Prior history of febrile neutropenia
References
Publications (0)
Data not yet available
No reference posted for this study.